Breast Cancer Network Australia

Practical treatment strategies and novel therapies for HR positive/HER2 negative advanced breast cancer

Neil Vasan, Breast oncologist at Herbert Irving Comprehensive Cancer Center, shared a post on X:

“Fantastic review on state of the art PI3K pathway inhibitors in the clinic in breast cancer.

The future is bright!

Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2−) advanced breast cancer

Author: K. Fanucci, A. Giordano, T. Erick, S.M. Tolaney, S. Sammons.”

Practical treatment strategies and novel therapies for HR positive/HER2 negative advanced breast cancer

Practical treatment strategies and novel therapies for HR positive/HER2 negative advanced breast cancer

A. Giordano Breast Cancer cancer K. Fanucci Neil Vasan OncoDaily Oncology PI3K S. Sammons S.M. Tolaney T. Erick